Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my ...

The backlog for contract oil driller Valaris remains strong. Read why recent share buybacks signal management’s confidence ...

Rivian's initial promise has faded amid ongoing losses, weak BEV demand, and significant capital burn. Click here to read an ...

Within the S&P 500, 32 stocks now have market caps of at least $250 billion. Of those, four have traded at all-time highs ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

Healthcare Realty Trust is dealing with post-merger challenges and volatility. Read my analysis of HR and why its HOLD rating ...

We asked Seeking Alpha analysts Kenio Fontes and Daniel Jones for their picks. Kenio Fontes: Two companies stand out for me ...

Blue Owl Capital Corporation outperforms with a 2% Q1 NAV return, solid portfolio quality, low non-accruals & first-lien ...

Northern Dynasty Minerals is a 'Hold' for risk-tolerant investors amidst bullish copper/gold trends. Click here to read my ...

Explore the explosive fallout between Elon Musk and Donald Trump, from political endorsements to shocking allegations, and ...

Booking Holdings' growth is slowing, with choppy bookings trends and decelerating revenue. Click here to find out why I ...

Brown-Forman faces challenges with demand weakness, pricing pressure, and profit headwinds. Click here to find out why BF.B ...